A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing ...

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in ...

A hidden “jack-in-the-box” mechanism inside T cells may hold the key to unlocking more powerful cancer immunotherapies.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has entered into two separate agreements with Pfizer Inc. (NYSE:PFE) that will see the companies collaborate on T-cell receptor (TCR) research to ...

Ryan Notti (left) and Thomas Walz (right) discovered new characteristics of a T cell receptor that are essential to a variety ...

STEM-engineered CAR T cells performed as well as or better against cancer cells than did FDA-approved CAR T cells and kept their cancer-fighting abilities for longer.

Its End-to-End Platform generates optimal 3S (sensitive, specific and safe) T cell receptors with unique and distinctive attributes that are utilized in multiple therapeutic modalities, such as T cell ...

This study provides useful insights into addressing the question of whether the prevalence of autoimmune disease could be driven by sex differences in the T cell receptor (TCR) repertoire, correlating ...

2022—Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) TCR and BCR kits, a family of multiplex-PCR, NGS-based assays that enable profiling of up to all seven T ...